UOC
ICPT

UBS O'Connor’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

UBS O'Connor’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-14,919
Closed -$2.13M – 514
2016
Q2 		$2.13M Buy
+14,919
New +$2.18M 0.05% 245

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS O'Connor's ICPT Position: Q3 2016 in Review

UBS O'Connor sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2016, closing a stake of 14,919 shares — an estimated $2.13M sold.

UBS O'Connor first reported a position in ICPT in Q2 2016 and held it in 1 quarter. The position peaked at $2.13M in Q2 2016. 172 funds tracked by Wall St. Rank hold ICPT as of Q3 2016.

  • UBS O'Connor reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • UBS O'Connor sold 14,919 Intercept Pharmaceuticals, Inc. shares in Q3 2016, an estimated $2.13M.
  • UBS O'Connor first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
  • UBS O'Connor's Intercept Pharmaceuticals, Inc. position peaked at $2.13M in Q2 2016.
  • 172 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2016.

Based on UBS O'Connor's 13F filing for Q3 2016, filed 14 Nov 2016.